Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2…
<!-- Name:DistributionId Value:8825608 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Ashvattha
Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of…
<!-- Name:DistributionId Value:8742661 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Ashvattha Therapeutics Announces Publication of Data in Science Translational…
REDWOOD CITY, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced…